GlassScriptPhysician profile
Donna Lagda Mather
NPI 1790243699
$1,531.44
in general payments reported to CMS, 2019-2025
24 companies · $29.58 in 2025
The $29.58 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $500 · 2023: $792 · 2024: $210 · 2025: $29.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026 · Education: $5.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.95 |
| Education | $5.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $249.96 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $238.58 | 2022-2024 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $183.58 | 2022-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $128.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $113.13 | 2022-2023 | |
| Dexcom, INC. | $101.94 | 2022-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $69.50 | 2022-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $64.29 | 2022-2023 | Wegovy |
| Abbvie INC. | $51.62 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $37.26 | 2023 | Acthar |
| Travere Therapeutics, INC. | $30.01 | 2023 | |
| Astellas Pharma US INC | $29.86 | 2024 | Veozah |
| Pfizer INC. | $25.63 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.77 | 2022 | |
| Opko Pharmaceuticals, LLC | $24.24 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.62 | 2023 | Ultomiris |
| Exact Sciences Corporation | $22.59 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $18.56 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Seqirus USA INC | $18.32 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Sanofi-Aventis U.S. LLC | $16.32 | 2022 | |
| Hologic Sales and Service, LLC | $16.25 | 2025 | Aptima |
| Merck Sharp & Dohme LLC | $16.06 | 2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Abbott Laboratories | $14.41 | 2023 | Freestyle Libre 3 |
| Organon LLC | $13.33 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Mather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.